Xeloda (Gastric Cancer) report

www.vnsc111.com

2018-10-09

:(TNM)::GastricCancerIncidenceandMortality,200820305Table2:GastricCancer,EstimatedGlobalMarket($bn),200920207Table3:OverallSurvivalResults13Table4:ResultsofSecondPhaseIIITrial14Table5:DrugRiskBenefitScoreofXeloda15Table6:AnnualCostofTherapyofXeloda,TheUS18Table7:GastricCancer,TheUS,EU-5andJapan,EstimatedSalesofXeloda($m),2007202019Table8:GastricCancer,TheUS,EstimatedSalesofXeloda($m),2012202020Table9:GastricCancer,EU-5,EstimatedSalesofXeloda($m),2007202021Table10:GastricCancer,Japan,EstimatedSalesofXeloda($m),:PercentageDistributionoftheTop20Cancers4Figure2:Fatality=[(%DistributionofIncidence)-(%DistributionofMortality)]oftheTop20Cancers5Figure3:PerCapitaCigaretteConsumptionCurve,theUS,1976-20066Figure4:EstimatedGlobalGastricCancerMarket,200920207Figure5:Oncology,Global,Incidence(inmillion),200820308Figure6:GastricCancer,Global,Incidence(inmillion),200820308Figure7:BroadClassificationofGastricCancerintheUSandEU10Figure8:BroadClassificationofGastricCancerinJapan10Figure9:DetailedTNMClassification11Figure10:ClassificationofGastricCancerintheUSandEU-512Figure11:ClassificationofGastricCancerinJapan12Figure12:DrugModelDiagramofXelodaintheUSandEU16Figure13:DrugModelDiagramofXelodainJapan17Figure14:GastricCancer,TheUS,EU-5andJapan,EstimatedSalesofXeloda($m),2007202019Figure15:GastricCancer,TheUS,EstimatedSalesofXeloda($m),2012-202020Figure16:GastricCancer,EU-5,EstimatedSalesofXeloda($m),2007-202021Figure17:GastricCancer,Japan,EstimatedSalesForecastofXeloda($m),2011-202022NO:12-12。